2026 Global: Cardiopulmonary Autotransfusion System Market -Competitive Review (2032) report
Description
The 2026 Global: Cardiopulmonary Autotransfusion System Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiopulmonary autotransfusion system market by geography and historical trend. The scope of the report extends to sizing of the cardiopulmonary autotransfusion system market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Haemonetics Corporation, LivaNova PLC, Medtronic plc, Fresenius Kabi (Fresenius SE group), Terumo Corporation, Becton Dickinson (BD), Stryker Corporation, Getinge/Atrium Medical, Zimmer Biomet, and Braile Biomédica are among the ten major companies shaping the cardiopulmonary autotransfusion system market, each contributing distinct product portfolios, geographic reach, and innovation foci.
Haemonetics is a leading cell-salvage specialist known for its Cell Saver product family and continual software and automation upgrades that emphasize workflow efficiency and perioperative blood management analytics, making it a key competitor in capital equipment and disposables for autotransfusion systems. LivaNova has long-standing leadership in cardiopulmonary technologies and positions its XTRA autotransfusion line as a high-performance solution leveraging three decades of cardiac bypass experience and global adoption across perfusion programs. Medtronic competes with advanced autotransfusion platforms such as the autoLog IQ series, focusing on sensor-based control, compact design, and integration with hospital workflows to deliver high red blood cell yields and ease of use in cardiac and orthopedic settings. Fresenius Kabi (part of Fresenius SE) provides continuous-flow autotransfusion systems and consumables, leveraging the parent group’s broad distribution channels and emphasis on filtration and compliance with transfusion standards across diverse patient populations.
Terumo, through its Terumo Cardiovascular group, brings legacy perfusion and autotransfusion expertise—combining centrifugal and membrane filtration technologies with a strong presence in cardiac surgery markets and established partnerships for distribution of continuous autotransfusion systems. Becton Dickinson (BD) participates in the market via capital devices and disposables, leveraging a broad infection-control and perioperative product portfolio to cross-sell autotransfusion solutions into existing hospital relationships. Stryker addresses high-acuity surgical environments with ergonomic autotransfusion systems and consumables designed for rapid setup, infection control, and staff efficiency in trauma and orthopedic theatres. Getinge, including Atrium Medical within its group, emphasizes user-centric interfaces, OR integration, and robust after-sales support, targeting procurement-driven hospital systems and international distribution networks.
Zimmer Biomet and Braile Biomédica represent additional major players with regional strengths and specialized offerings: Zimmer Biomet leverages orthopedic market access to supply autotransfusion systems into surgical suites where blood salvage is routine, while Braile Biomédica serves Latin American markets with locally adapted autotransfusion equipment and consumables. Collectively these ten companies drive market dynamics through continuous product development (software-driven automation, continuous-flow technologies, platelet-preserving approaches), strategic distribution partnerships, and regulatory activity that expand adoption of cardiopulmonary autotransfusion in cardiac, orthopedic, trauma, and transplant procedures.
Market leadership is differentiated by companies’ balance of capital systems versus disposable consumables, investment in automation and sensor technologies, and geographic penetration; firms with integrated perfusion and cardiopulmonary portfolios (LivaNova, Terumo, Haemonetics, Medtronic, Fresenius) maintain the strongest positions while BD, Stryker, Getinge/Atrium, Zimmer Biomet, and Braile concentrate on complementary channels and regional growth to expand overall market share.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiopulmonary autotransfusion system market by geography and historical trend. The scope of the report extends to sizing of the cardiopulmonary autotransfusion system market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Haemonetics Corporation, LivaNova PLC, Medtronic plc, Fresenius Kabi (Fresenius SE group), Terumo Corporation, Becton Dickinson (BD), Stryker Corporation, Getinge/Atrium Medical, Zimmer Biomet, and Braile Biomédica are among the ten major companies shaping the cardiopulmonary autotransfusion system market, each contributing distinct product portfolios, geographic reach, and innovation foci.
Haemonetics is a leading cell-salvage specialist known for its Cell Saver product family and continual software and automation upgrades that emphasize workflow efficiency and perioperative blood management analytics, making it a key competitor in capital equipment and disposables for autotransfusion systems. LivaNova has long-standing leadership in cardiopulmonary technologies and positions its XTRA autotransfusion line as a high-performance solution leveraging three decades of cardiac bypass experience and global adoption across perfusion programs. Medtronic competes with advanced autotransfusion platforms such as the autoLog IQ series, focusing on sensor-based control, compact design, and integration with hospital workflows to deliver high red blood cell yields and ease of use in cardiac and orthopedic settings. Fresenius Kabi (part of Fresenius SE) provides continuous-flow autotransfusion systems and consumables, leveraging the parent group’s broad distribution channels and emphasis on filtration and compliance with transfusion standards across diverse patient populations.
Terumo, through its Terumo Cardiovascular group, brings legacy perfusion and autotransfusion expertise—combining centrifugal and membrane filtration technologies with a strong presence in cardiac surgery markets and established partnerships for distribution of continuous autotransfusion systems. Becton Dickinson (BD) participates in the market via capital devices and disposables, leveraging a broad infection-control and perioperative product portfolio to cross-sell autotransfusion solutions into existing hospital relationships. Stryker addresses high-acuity surgical environments with ergonomic autotransfusion systems and consumables designed for rapid setup, infection control, and staff efficiency in trauma and orthopedic theatres. Getinge, including Atrium Medical within its group, emphasizes user-centric interfaces, OR integration, and robust after-sales support, targeting procurement-driven hospital systems and international distribution networks.
Zimmer Biomet and Braile Biomédica represent additional major players with regional strengths and specialized offerings: Zimmer Biomet leverages orthopedic market access to supply autotransfusion systems into surgical suites where blood salvage is routine, while Braile Biomédica serves Latin American markets with locally adapted autotransfusion equipment and consumables. Collectively these ten companies drive market dynamics through continuous product development (software-driven automation, continuous-flow technologies, platelet-preserving approaches), strategic distribution partnerships, and regulatory activity that expand adoption of cardiopulmonary autotransfusion in cardiac, orthopedic, trauma, and transplant procedures.
Market leadership is differentiated by companies’ balance of capital systems versus disposable consumables, investment in automation and sensor technologies, and geographic penetration; firms with integrated perfusion and cardiopulmonary portfolios (LivaNova, Terumo, Haemonetics, Medtronic, Fresenius) maintain the strongest positions while BD, Stryker, Getinge/Atrium, Zimmer Biomet, and Braile concentrate on complementary channels and regional growth to expand overall market share.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.